Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00006104. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Institutional Phase II Pilot Trial With Weekly Docetaxel and Herceptin as First or Second Line Therapy for HER2/Neu Overexpressing Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab plus docetaxel in treating women who have recurrent or metastatic breast cancer.
Study identification
- NCT ID
- NCT00006104
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 1998 (Type not available)
- Primary completion
- Jul 2003 (Actual)
- Completion
- Jul 2003 (Actual)
- Last update posted
- Aug 14, 2012
1998 – 2003
United States locations
- U.S. sites
- 15
- U.S. states
- 5
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Hospital | Mobile | Alabama | 36608 | — |
| Robert H. Lurie Comprehensive Cancer Center, Northwestern University | Chicago | Illinois | 60611-3013 | — |
| Evanston Hospital | Evanston | Illinois | 60201 | — |
| Owensboro Medical Health System | Owensboro | Kentucky | 42303 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Erlanger Health Systems | Chattanooga | Tennessee | 37403 | — |
| Memorial Health Care System | Chattanooga | Tennessee | 37404 | — |
| Williamson Medical Center | Franklin | Tennessee | 37067 | — |
| Jackson-Madison County Hospital | Jackson | Tennessee | 38301 | — |
| Methodist/Thompson Oncology Research | Knoxville | Tennessee | 37916 | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37920 | — |
| Boston Baskin Cancer Group | Memphis | Tennessee | 38104 | — |
| St. Thomas Health Services | Nashville | Tennessee | 37205 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232-6838 | — |
| Methodist Medical Center of Oak Ridge | Oak Ridge | Tennessee | 37831 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00006104, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 14, 2012 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00006104 live on ClinicalTrials.gov.